Leukemia, Acute Lymphoblastic

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

Erwinase Master Treatment Protocol

A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy

Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)

Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses

CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL

Safety of Expanded Haploidentical Natural Killer Cells for Leukemia

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT

Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia

iCare for Cancer Patients

Acute Lymphoblastic Leukemia Registry at Asan Medical Center

Vincristine PK and PD in the AYA Population Compared to Younger Children